Association of prenatal phenobarbital and phenytoin exposure with small head size at birth and with learning problems

A B Dessens1, P T Cohen-Kettenis, G J Mellenbergh

  • 1Academic Medical Center, University of Amsterdam, Graduate School Neurosciences, The Netherlands.

Insights

Prenatal exposure to anticonvulsants like phenobarbital and phenytoin can affect fetal head size. While cognitive function in adulthood may be normal, some exposed individuals experience learning problems or mental retardation.

Area of Science:

  • Neuroscience
  • Developmental Psychology
  • Pharmacology

Background:

  • Prenatal exposure to anticonvulsant medications is associated with developmental abnormalities.
  • Cognitive impairments observed in infancy following prenatal anticonvulsant exposure raise questions about long-term effects.
  • The persistence of these cognitive deficits into adulthood remains largely uninvestigated.

Purpose of the Study:

  • To investigate the long-term effects of prenatal anticonvulsant exposure on cognitive functioning in adulthood.
  • To examine the relationship between prenatal anticonvulsant exposure, head size, and cognitive outcomes in adults.
  • To determine if cognitive impairments observed in infancy persist after puberty.

Main Methods:

  • A retrospective study involving 172 neonates exposed prenatally to anticonvulsants and 168 matched controls.
  • Measurement of occipitofrontal circumference (OFC) in neonates to assess head size.
  • A follow-up assessment of cognitive capacities in adulthood for individuals included in the retrospective study.

Main Results:

  • Prenatal exposure to phenobarbital + phenytoin resulted in a significantly smaller occipitofrontal circumference (OFC) compared to controls.
  • No overall difference in cognitive functioning was found between the exposed and control groups in adulthood.
  • A higher prevalence of persistent learning problems (12% vs 1%) and mental retardation was observed in the exposed group.

Conclusions:

  • The combination of phenobarbital and phenytoin impacts fetal head development (OFC).
  • A smaller OFC in exposed individuals did not correlate with cognitive functioning in adulthood.
  • Prenatal anticonvulsant exposure may increase the risk for learning difficulties and mental retardation in susceptible individuals.
Abstract

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.